Curis, Inc. (CRIS)

NCM – Real vaqt narxi. Valyuta: USD

0.32

+0.12 (55.98%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.29

-0.03 (-9.66%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

13.05.2026

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

12.05.2026

Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

05.05.2026

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m.

28.04.2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

15.04.2026

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

19.03.2026

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

19.03.2026

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

19.03.2026

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

09.01.2026

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

07.01.2026

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis, Inc. (CRIS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Curis, Inc. (CRIS)

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Videolar

No Data

Press-relizlar

Curis Provides First Quarter 2026 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Videolar

No Data

Press-relizlar

Curis Provides First Quarter 2026 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Search stocks

Curis, Inc. (CRIS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Curis, Inc. (CRIS)

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Videolar

No Data

Press-relizlar

Curis Provides First Quarter 2026 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Videolar

No Data

Press-relizlar

Curis Provides First Quarter 2026 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds